

## **Hyloris shareholders approve all resolutions of the Extraordinary General Meeting by more than 99% and postpone the Annual General Meeting**

- All documents related to the 2024 AGM and EGM are available on the website

**Regulated Information - Liège, Belgium – 11 June 2024 – 6PM CET - Hyloris Pharmaceuticals SA (Euronext Brussels: HYL)**, a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announces the approval of all resolutions by more than 99% at its Extraordinary General Meeting (EGM) and the postponement of its Annual General Meeting (AGM). The shareholders represented 54,18 % of the company shares at both the EGM and AGM.

A new General Meeting will be convened upon the publication of the annual report and the financial statements for the fiscal year ended December 31, 2023.

### **About Hyloris Pharmaceuticals SA**

Hyloris is a specialty biopharma company focused on innovating, reinventing, and optimizing existing medications to address important healthcare needs and deliver relevant improvements for patients, healthcare professionals and payors.

The Company's development strategy primarily focuses on leveraging established regulatory pathways, such as the FDA's 505(b)2 pathway in the U.S or equivalent regulatory frameworks in other regions which are specifically designed for pharmaceuticals for which safety and efficacy of the molecule have already been established. This approach can reduce the clinical burden required for market entry, and significantly shorten the development timelines, leading to reduced costs and risks.

Hyloris has built a broad, patented portfolio of 18 reformulated and repurposed value-added medicines that have the potential to offer significant advantages over existing alternatives. Two products are currently in early phases of commercialization in collaboration with commercial partners: Sotalol IV for the treatment of atrial fibrillation, and Maxigesic® IV, a non-opioid post-operative pain treatment. In addition to its core strategic focus, the Company has 1 approved high barrier generic product launched in the U.S. and 2 high barrier generic products in development.

For more information, visit [www.hyloris.com](http://www.hyloris.com) and follow-us on LinkedIn.



**For more information, contact Hyloris Pharmaceuticals:**

Stijn Van Rompay, CEO

[stijn.vanrompay@hyloris.com](mailto:stijn.vanrompay@hyloris.com)

+32 (0)4 346 02 07

Jean-Luc Vandebroek, CFO

[jean-luc.vandebroek@hyloris.com](mailto:jean-luc.vandebroek@hyloris.com)

+32 (0)478 27 68 42

**Disclaimer and forward-looking statements**

Hyloris means “high yield, lower risk”, which relates to the 505(b)(2) regulatory pathway for product approval on which the Company focuses, but in no way relates or applies to an investment in the Shares. Certain statements in this press release are “forward-looking statements.” These forward-looking statements can be identified using forward-looking terminology, including the words “believes”, “estimates”, “anticipates”, “expects”, “intends”, “may”, “will”, “plans”, “continue”, “ongoing”, “potential”, “predict”, “project”, “target”, “seek” or “should”, and include statements the Company makes concerning the intended results of its strategy. These statements relate to future events or the Company’s future financial performance and involve known and unknown risks, uncertainties, and other factors, many of which are beyond the Company’s control, that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

